Videos

Joshua Mali, MD, talks about how the FDA approval of faricimab will change the treatment landscape for wet AMD and DME.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Dr. McDonnell highlights inspiring moments from the 2021 annual meeting of the American Academy of Ophthalmology, along with a look ahead to next year’s conference in Chicago.

Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.

Peter J. McDonnell, MD, shares some of many highlights from this year’s annual meeting of the American Academy of Ophthalmology in New Orleans.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

EyeCon co-chairs Peter J. McDonnell, MD, and Oluwatosin U. Smith, MD, discuss the virtual conference and its relevance to ophthalmologists across the country.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.

Ash Abbey, MD, discusses the COED trial, testing the efficacy of combining steroid and anti-VEGF therapy in patients with diabetic macular edema.

At ASRS, David Brown, MD, reported positive results at the head-to-head endpoints of KESTREL and KITE, but with continuing concerns about inflammation.

Dr. Timothy G. Murray discusses the 5-year follow-up data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.

Nathan Steinle, MD, discusses top-line results of the OAKS and DERBY trials, testing the efficacy of pegcetacoplan for the treatment of geographic atrophy.

Carl Regillo, MD, takes us through the history of the port delivery system, from ideation to FDA approval.

Dr. Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular edema (DME) patients.

Nimesh Patel, MD, discusses his presentation entitled, "Scleral-Sutured Intraocular Lens Dislocations Secondary to Eyelet Fractures" at ASRS.

In his presentation at ASRS 2021, Dr. Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular edema in patients with retinal vein occlusion.